Syros Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Syros Pharmaceuticals

08/08/2023 14:33

* Syros Pharmaceuticals Inc  SYRS.OQ  reported a quarterly
adjusted loss of $1.30​​ per share for the quarter ended in
June. The mean expectation of five analysts for the quarter was
for a loss of $1.13 per share.
    * Revenue fell 54.9% to $2.83 million from a year ago;
analysts
expected $3.50 million. 
    * Syros Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of $1.30​.
    * The mean earnings estimate of analysts had fallen by
about 0.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Syros Pharmaceuticals Inc shares had risen by 16.8% this
quarter and gained 2.5% so far this year.
    * The company reported a quarterly loss of $36.26 million.
    * Wall Street's median 12-month price target for Syros
Pharmaceuticals Inc is $15.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 8 at 01:33 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -1.13          -1.30          Missed
 Mar. 31 2023      -1.09          -0.85          Beat
 Dec. 31 2022      -1.35          -0.17          Beat
 Sep. 30 2022      -4.01          -3.21          Beat